Abeona Therapeutics (PCJ) Stock Statistics & Valuation Metrics

Abeona Therapeutics has a market cap or net worth of CHF255.88M. The enterprise value is $291.23M.

Abeona Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Abeona Therapeutics’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is -43.98%.

The current PE Ratio of Abeona Therapeutics is 4.9. Abeona Therapeutics’s PEG ratio is -0.02.

In the last 12 months, Abeona Therapeutics had revenue of 5.82M and earned 71.18M in profits. Earnings per share was 1.34.

In the last 12 months, operating cash flow was -77.73M and capital expenditures -7.51M, giving a free cash flow of -85.24M billion.

Abeona Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Abeona Therapeutics upcoming earnings date is Aug 12, 2026, TBA (Confirmed).

Abeona Therapeutics as a current ratio of 6.93, with Debt / Equity ratio of 15.99%

In the past 12 months, Abeona Therapeutics has paid 100.00K in taxes.

Abeona Therapeutics EV to EBITDA ratio is -2.63, with an EV/FCF ratio of -2.68.

Abeona Therapeutics has CHF168.27M in cash and marketable securities with CHF23.17M in debt, giving a net cash position of CHF145.10M billion.

Gross margin is 51.93%, with operating margin of -1536.91%, and net profit margin of 1223.08%.

The average price target for Abeona Therapeutics is CHF15.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy